Skip to main content
Premium Trial:

Request an Annual Quote

Quest Extends HPV Marketing Deal With Digene for Four More Years

NEW YORK (GenomeWeb News) — Digene this week said it has extended by four years a three-year agreement with Quest Diagnostics under which Quest will market Digene’s test for human papillomavirus.
  
Digene will continue to supply Quest’s labs with the instrumentation and reagents for HPV testing, the company said.
 
Digene also said that Quest will “continue its efforts with Digene to educate and promote HPV screening along with the Pap test to its customer base of hospitals, physicians, and other healthcare providers.”

The test is used to detect HPV, which is “the recognized cause of cervical cancer,” and has been approved by the US Food and Drug Administration for use along with a Pap test in women aged 30 and older as a cervical cancer screen, Digene said.

 
Financial terms of the agreement were not released.

The Scan

Study Reveals New Details About Genetics of Major Cause of Female Infertility

Researchers in Nature Medicine conducted a whole-exome sequencing study of mote than a thousand patients with premature ovarian insufficiency.

Circulating Tumor DNA Shows Potential as Biomarker in Rare Childhood Cancer

A study in the Journal of Clinical Oncology has found that circulating tumor DNA levels in rhabdomyosarcoma may serve as a biomarker for prognosis.

Study Recommends Cancer Screening for Dogs Beginning Age Seven, Depending on Breed

PetDx researchers report in PLOS One that annual cancer screening for dogs should begin by age seven.

White-Tailed Deer Harbor SARS-CoV-2 Variants No Longer Infecting Humans, Study Finds

A new study in PNAS has found that white-tailed deer could act as a reservoir of SARS-CoV-2 variants no longer found among humans.